$3.86
-5.9%Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ZURA • NASDAQ
| Zura Bio Limited Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-68.7M | -52.4M | -60.6M | -27.3M | 8.4M | |
49K | 9K | 0.0 | 0.0 | 0.0 | |
12.3M | 16.8M | 9.7M | 334K | 0.0 | |
-4.9M | 5.2M | 30.7M | 22.3M | -9.3M | |
-3.6M | 2.3M | 5.1M | 3.5M | -235.6K | |
-64.8M | -28.1M | -15.1M | -1.2M | -1.1M | |
INVESTING ACTIVITIES | |||||
-113K | -75K | -8M | -12M | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -139.4M | |
0.0 | -5M | 0.0 | 0.0 | 0.0 | |
-113K | -5.1M | -8M | -12M | -139.4M | |
FINANCING ACTIVITIES | |||||
5.2M | 60.8M | 116.4M | 0.0 | 140.8M | |
0.0 | 0.0 | -10M | 7.6M | -117.4K | |
-7.4M | 49.1M | 14.9M | -2.8M | 505K | |
-2.2M | 109.8M | 121.3M | 14.8M | 141.2M | |
CASH FLOW SUMMARY | |||||
-67.1M | 76.7M | 98.2M | 1.6M | 729.2K | |
176.5M | 99.8M | 1.6M | 0.0 | 0.0 | |
109.4M | 176.5M | 99.8M | 1.6M | 729.2K | |
-64.9M | -28.2M | -23.1M | -13.2M | -1.1M |
ZURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | February 26, 2026 | February 24, 2026 | 2026 |
Continue your ZURA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.